PDF(Pubmed)
Abstract：
Antibody-drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor antibody drugs. Every year, exciting new developments and innovations in the treatment of urological tumors are introduced at the American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. In this article, we summarize some of the most impressive advances in new clinical trials and clinical data on ADCs in the 2023 ASCO-GU Cancers Symposium for the treatment of urothelial carcinoma.
摘要：
抗体-药物缀合物(ADC)将小分子药物的细胞毒性与抗体靶向相结合。由于它们精确而强大的效果，成为抗肿瘤抗体药物研发的新热点和重要趋势。每年,在泌尿系肿瘤的治疗令人兴奋的新进展和创新在临床肿瘤-泌尿生殖系统（ASCO-GU）癌症研讨会的美国学会介绍。在这篇文章中,我们总结了2023年ASCO-GU癌症治疗尿路上皮癌研讨会上有关ADC的新临床试验和临床数据方面的一些最令人印象深刻的进展.
